ASCO 2023 | What future does ctDNA have as a biomarker in breast cancer?

Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, comments on the emerging role of circulating tumor DNA in the management of breast cancer. Whilst ctDNA has potential to enable adaptive therapies for patients and enhanced patient monitoring, additional research is needed to fully evaluate the efficacy of ctDNA as a biomarker. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.